Exact Mass: 327.1120048
Exact Mass Matches: 327.1120048
Found 118 metabolites which its exact mass value is equals to given mass value 327.1120048,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Loxapine
Loxapine is only found in individuals that have used or taken this drug. It is an antipsychotic agent used in schizophrenia. [PubChem]Loxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Loxapine is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent[1][4].
N-(4-Hydroxycinnamoyl)tyrosine
Natural food antioxidant. Isolated from cocoa liquor (Theobroma cacao). N-(4-Hydroxycinnamoyl)tyrosine is found in cocoa and cocoa products and cocoa powder. N-(4-Hydroxycinnamoyl)tyrosine is found in cocoa and cocoa products. Natural food antioxidant. It is isolated from cocoa liquor (Theobroma cacao).
desethylamodiaquine
desethylamodiaquine is a metabolite of amodiaquine. Amodiaquine (trade names Camoquin, Flavoquine) is a 4-aminoquinoline compound related to chloroquine, used as an antimalarial and anti-inflammatory agent. Amodiaquine has been shown to be more effective than chloroquine in treating CRPF (chloroquine-resistant Plasmodium falciparum) malaria infections and may afford more protection than chloroquine when used as weekly prophylaxis. Amodiaquine, like chloroquine, is generally well tolerated. (Wikipedia)
Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-
(5S)-5-(7-Benzofuranyl)-8-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
1,3-Dioxolo(4,5-g)furo(2,3-b)quinoline, 9-methoxy-4-((3-methyl-2-butenyl)oxy)-
3-Methyl-6-oxo-1-phenyl-4-(3-pyridinyl)-6,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile
(S,E)-2-(3-(3,4-dihydroxyphenyl)acrylamido)-3-phenylpropanoic acid|2-[3-(3,4-dihydroxy-phenyl)-acryloylamino]-3-phenylpropionic acid|N-trans-caffeoyl-L-phenylalanine
8-Hydroxy-5,7-Dimethoxy-4-(4-methoxyphenyl)-2(1H)-quinolinone
C18H17NO5_L-Tyrosine, N-[(2Z)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]
C18H17NO5_L-Tyrosine, N-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]
loxapine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Loxapine is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent[1][4].
Tranilast
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects[1]. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells[2]. trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases, atopic and fibrotic pathologies, and can also inhibit angiogenesis. The antiproliferative properties of tranilast were found that tranilast elicited an inhibitory effect on fibroblast proliferation in vitro and also suppressed collagen production both in vitro and in vivo . Tranilast also reduced the release of chemical mediators from mast cells and suppressed hypersensitivity reactions. [1] Three-week-old C57Bl/10 and mdx mice received tranilast (~300 mg/kg) in their food for 9 weeks, after which fibrosis was assessed through histological analyses, and functional properties of tibialis anterior muscles were assessed in situ and diaphragm muscle strips in vitro. Tranilast administration did not significantly alter the mass of any muscles in control or mdx mice, but it decreased fibrosis in the severely affected diaphragm muscle by 31\% compared with untreated mdx mice (P< 0.05) [2].
(2S)-3-(4-hydroxyphenyl)-2-[[(Z)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]propanoic acid
PC(2:0/1:0)[U]
C11H22NO8P (327.10829820000004)
N-trans-P-Coumaroyltyrosine
3-[3-(4-methoxyphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid
2-(3,4-DIMETHOXYBENZYL)-3-OXOISOINDOLINE-4-CARBOXYLIC ACID
2-CBZ-6-Hydroxy-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid
7-(Dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol hydrobromide (1:1)
9-(3,4-dichlorophenoxy)-3-methyl-3-azaspiro[5.5]undecane
(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester tosylate salt
7-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL HYDROBROMIDE
8-Hydroxy-DPAT hydrobromide
8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site[1].
BENZYL 4-(((METHYLSULFONYL)OXY)METHYL)PIPERIDINE-1-CARBOXYLATE
2-(5-Chloro-2H-Benzotriazol-2-Yl)-6-(2-Methyl-2-Propanyl)-4-Vinylphenol
Verosudil
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
1-(5-(TERT-BUTYL)ISOXAZOL-3-YL)-3-(2-(TRIFLUOROMETHYL)PHENYL)UREA
N(ALPHA)-BOC-O-(DIMETHYLPHOSPHO)-L-THREO
C11H22NO8P (327.10829820000004)
7,7-dimethyl-3-[(3-nitrophenyl)methyl]-6,8-dihydrochromene-2,5-dione
Zolamine hydrochloride
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Ethyl 3-hydroxy-3-methyl-1-tosylpyrrolidine-2-carboxylate
4-Methyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-YL)benzenesulfonamide
(+)-5-(7-benzofuranyl)-8-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol
1H-3-Benzazepin-7-ol, 5-(7-benzofuranyl)-8-chloro-2,3,4,5-tetrahydro-3-methyl-, (S)-
4-[3-Methylsulfanylanilino]-6,7-dimethoxyquinazoline
[8-Methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-piperidin-1-ylmethanone
3-[(4-methoxybenzylidene)amino]-2,5,6-trimethylthieno[2,3-d]pyrimidin-4(3H)-one
4-(3,4-dimethoxyphenyl)-N-(3-methyl-2-pyridinyl)-2-thiazolamine
6-Amino-3-[(2-chlorophenyl)methyl]-2-propyl-4-quinazolinone
O3-(2-fluorobenzoyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carbohydroximamide
N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine
8-[2-(4-Chloro-3,5-dimethylphenoxy)ethoxy]quinoline
8-[2-(4-Chloro-2,5-dimethylphenoxy)ethoxy]quinoline
2-[(3-ethyl-2-quinolinyl)thio]-N-(5-methyl-3-isoxazolyl)acetamide
3-[2-Methoxy-6-(4-methoxyphenyl)-3-pyridinyl]-5-(methoxymethyl)-1,2,4-oxadiazole
5-(2,5-difluorophenyl)-N-(2,6-dimethylphenyl)-2-furancarboxamide
C19H15F2NO2 (327.10707940000003)
3-(4-methoxyphenyl)-3-(1-pyrrolyl)-N-(2-thiazolyl)propanamide
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester
2-[4-(Cyclohexylsulfamoyl)-2-methylphenoxy]acetic acid
4-[4-[(4-Fluorophenyl)methyl]-1-piperidinyl]thieno[2,3-d]pyrimidine
C18H18FN3S (327.12054000000006)
7-(diethylamino)-3,4-dioxo-10H-phenoxazine-1-carboxamide
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-propanoyloxypropyl] propanoate
C11H22NO8P (327.10829820000004)
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] butanoate
C11H22NO8P (327.10829820000004)
2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoic acid
M1001
M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 can be used in chronic kidney disease research[1].